Active Biotech AB Year-end report January - December 2016

Laquinimod

• The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
• The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017
• The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the second half of 2017
• Orphan Drug Designation granted in the US by the FDA ("US Food and Drug Administration")  for laquinimod for the treatment of Huntington's disease

ANYARA     

• A licensing agreement has been entered into with NeoTX Therapeutics Ltd

Tasquinimod, Paquinimod and SILC

• Out-licensing activities are continuing
• The European Patent Office has granted a patent application covering tasquinimod for use in the treatment of multiple myeloma
• Product patent for SILC substances granted by the European Patent Office

New share issue 

• Rights issue implemented in fourth quarter generating proceeds of SEK 53.7 M for the company after issue expenses

Financial summary

• Operating costs for full-year 2016 reduced by 62% (SEK 120.1 M) compared with 2015
   
• Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017

For further information, please contact:     

The report is also available at www.activebiotech.com.

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/b7db1773-1b32-4839-8243-826cdfe35a48